Company research

Explore company profiles, quarterly results, announcements and ownership disclosures.

Loading the company view…

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) — Stock Analysis

GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO), ISIN INE159A01016 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.

GLAXO last traded at ₹2876.90 (+0.11%), with a 52-week range of ₹2088.00 to ₹3121.10 (as of 23 Sep 2026).

Shareholding as of Jun 2026: promoters 75.00%, FIIs 4.79%, DIIs 7.80%, mutual funds 4.87%.

EquiSense Score (ECS): 75/100.

Data sourced from NSE and BSE filings. Educational — not investment advice.